Government ne CGHS labs ke liye rules bahut tight kar diye hain, jis se diagnostic market mein ek nayi debate chhid gayi hai. Investors ke liye ye compliance ka pressure badi diagnostic chains ke liye game-changer ho sakta hai.
Do-tier regulatory system ka chakkar
India ke healthcare sector mein aaj kal kaafi garam charcha chal rahi hai. Ek taraf CGHS-empanelled labs hain jinhe strict rules follow karne padte hain, aur dusri taraf aam private labs hain jahan rules ka enforcement utna tight nahi hai.
Kya hain ye strict requirements?
CGHS-empanelled labs ke liye NABL accreditation mandatory hai. Iske saath hi, full-time pathologists ki zarurat aur high-end equipment specifications ko pura karna zaruri hota hai. Jabki general private labs Clinical Establishment Rules 2018 ke under aati hain, jahan staffing mein thodi flexibility milti hai, jaise ki experienced science graduates ko rakhna.
Investors ke liye kya matlab hai?
Organized diagnostic sector ke liye ye ek bada mauka hai. Badi listed companies pehle se hi NABL norms aur professional standards follow karti hain. Chhote players ke liye itna heavy compliance cost uthana mushkil ho raha hai, jiske karan ya toh unhe market chhodna padega ya phir consolidations honge.
Future outlook
Agar government ne aane wale samay mein sabhi private centers ke liye universal NABL mandatory kar diya, toh poore sector ka cost of business badh jayega. Lekin, jo badi chains pehle se hi set-up hain, unhe iska kaafi bada competitive advantage milega. Investors ko is trend par nazar banaye rakhni chahiye.